Skip to main content

Table 1 Descriptive characteristics of the study participants (N: 79)

From: Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome

 

Mean (range)

Age (years)

56.7 (34–89)

 

N (%)

Histology

Benign

1 (1.3)

Malignant

78 (98.7)

  Invasive lobular carcinoma

15 (19.2)

  Invasive ductal carcinoma

55 (70.5)

  Miscellaneusa

4 (5.1)

  Unknownb

4 (5.1)

Grading (G)*

G 1–2

32 (41.0)

G3

40 (51.3)

Unknownc

6 (7.7)

Hormon receptor status*

dER+/ePgR+

57 (73.1)

ER+/PgR-

12 (15.4)

ER−/PgR-

6 (7.7)

Unknown f

3 (3.8)

Her2 Status*

Positive

12 (15.2)

Surgical procedures

Surgical procedures with curative intent

79 (100)

  Simple excision/lumpectomy

2 (2.5)

  Breast conserving surgery

29 (36.7)

  gMastectomy

23 (29.1)

  hNipple sparing mastectomy

19 (24.0)

  iSkin reducing mastectomy

6 (7.6)

Surgical procedures with recostructive intent

48 (60.7)

  Pre-pectoral DTIj

16 (33.3)

  Sub-pectoral DTI

4 (8.3)

  Pre-pectoral TEk

1 (2.1)

  Sub-pectoral TE

13 (27.1)

  Contralateral symmetrization

4 (8.3)

Surgical procedures with prophilactic intent**

  Concomitant bilateral oophorectomy

2 (2.5)

Neo-adjuvant chemotherapy

Yes

13 (16.7)

Pathologic complete response

Yes

5 (38.5)

lASA risk score

1–2

60 (76.0)

3–4

19 (24.0)

  1. Legend: aMiscellaneous: Special hystologic types, e.g., cribiform carcinoma, mucous carcinoma, medullary carcinoma, squamous carcinoma, papillary carcinoma, apocrine carcinoma; b Cases with unknown histology include: a. one patients with pCR following neo-adjuvant chemotherapy; b. one patient with inflammatory mastitis; c. one patient who underwent breast biopsy with no residual breast cancer at the histological assessment of residual breast; d. one patient who underwent lumpectomy with no residual breast cancer at the histological assessment of residual breast; cCases with unknown grading include: a. 3 cases with diagnostic workup and surgical cancer excision out of the Regina Elena National Cancer Institute; b. one patients with pCR following neo-adjuvant chemotherapy; c. one case of carcinomatous mastitis; d. one case who underwent lumpectomy with no residual breast cancer at the histological assessment of residual breast; d ER: Estrogen Receptors; e PgR: Progesterone Receptors; f Hormonal Receptor Status was unknown in the following: a. one case with diagnostic workup and surgical cancer excision out of the Regina Elena National Cancer Institute; b.. one patients who achieved pCR following neo-adjuvant chemotherapy; c. one case of carcinomatous mastitis; * For these variables, percentages were computed over a total number of 78 patients, i.e., the overall number of patients with histologically-confirmed breast malignancy, with the only case of histologically-proven benign tumor being excluded; ** For this variable, percentage was computed over a total number of 79, i.e., the overall number of surgical procedures performed; g Of the 23 mastectomies, 4 were bilateral mastectomies; h Of the 19 nipple sparing mastectomies, 5 were bilateral; i Of the 6 skin reducing mastectomies, 3 were bilateral; jDTI: Direct-to-Implant; k TE: Tissue Expander; lASA: Amercan Society of Anesthesiologists